Free Trial

OncoCyte (OCX) Stock Price, News & Analysis

OncoCyte logo
$2.70 +0.06 (+2.27%)
As of 03:59 PM Eastern

About OncoCyte Stock (NASDAQ:OCX)

Key Stats

Today's Range
$2.56
$2.76
50-Day Range
$2.60
$3.44
52-Week Range
$1.92
$4.75
Volume
53,063 shs
Average Volume
58,732 shs
Market Capitalization
$77.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.06
Consensus Rating
Moderate Buy

Company Overview

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

OncoCyte Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
57th Percentile Overall Score

OCX MarketRank™: 

OncoCyte scored higher than 57% of companies evaluated by MarketBeat, and ranked 496th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OncoCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    OncoCyte has only been the subject of 4 research reports in the past 90 days.

  • Read more about OncoCyte's stock forecast and price target.
  • Earnings Growth

    Earnings for OncoCyte are expected to grow in the coming year, from ($2.57) to ($1.40) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of OncoCyte is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of OncoCyte is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    OncoCyte has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about OncoCyte's valuation and earnings.
  • Percentage of Shares Shorted

    1.32% of the float of OncoCyte has been sold short.
  • Short Interest Ratio / Days to Cover

    OncoCyte has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in OncoCyte has recently decreased by 7.88%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    OncoCyte does not currently pay a dividend.

  • Dividend Growth

    OncoCyte does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.32% of the float of OncoCyte has been sold short.
  • Short Interest Ratio / Days to Cover

    OncoCyte has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in OncoCyte has recently decreased by 7.88%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    OncoCyte has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for OncoCyte this week, compared to 1 article on an average week.
  • Search Interest

    6 people have searched for OCX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, OncoCyte insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.05% of the stock of OncoCyte is held by insiders.

  • Percentage Held by Institutions

    55.35% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about OncoCyte's insider trading history.
Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

OCX Stock News Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Headlines

OCX Stock Analysis - Frequently Asked Questions

OncoCyte's stock was trading at $2.38 at the beginning of the year. Since then, OCX stock has increased by 13.4% and is now trading at $2.70.
View the best growth stocks for 2025 here
.

OncoCyte Co. (NASDAQ:OCX) posted its quarterly earnings data on Monday, May, 12th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.02. The company had revenue of $2.14 million for the quarter, compared to the consensus estimate of $0.13 million. OncoCyte had a negative net margin of 6,122.29% and a negative trailing twelve-month return on equity of 269.32%.
Read the conference call transcript
.

Shares of OncoCyte reverse split before market open on Tuesday, July 25th 2023. The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Top institutional shareholders of OncoCyte include Broadwood Capital Inc. (39.90%), AWM Investment Company Inc. (9.87%), Wealthedge Investment Advisors LLC (0.26%) and FNY Investment Advisers LLC (0.14%). Insiders that own company stock include Broadwood Partners, LP, Pura Vida Investments, Llc, Andrea S James, Andrew Arno, Alfred D Kingsley, Ronald Asbury Andrews, Andrew J Last and Josh Riggs.
View institutional ownership trends
.

Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that OncoCyte investors own include Alibaba Group (BABA), Meta Platforms (META), Fulcrum Therapeutics (FULC), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY) and Ford Motor (F).

Company Calendar

Last Earnings
5/12/2025
Today
6/12/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OCX
Employees
120
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.06
High Stock Price Target
$8.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+127.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$27.78 million
Net Margins
-6,122.29%
Pretax Margin
-6,085.19%

Debt

Sales & Book Value

Annual Sales
$3.84 million
Price / Cash Flow
N/A
Book Value
$2.48 per share
Price / Book
1.08

Miscellaneous

Free Float
17,177,000
Market Cap
$76.36 million
Optionable
No Data
Beta
0.97
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:OCX) was last updated on 6/12/2025 by MarketBeat.com Staff
From Our Partners